Skip to main content
    T

    Tonix Pharmaceuticals Holding Corp (TNXP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.88
    -0.13 (-4.32%)

    Market Cap: $58.49M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(15/40)
    Avg Surprise
    -2.22%

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$2.41
    Range-$2.45 - -$2.39
    8 analysts
    Revenue Consensus
    $20.70M
    Range$16.17M - $24.15M
    8 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$2.42
    Range-$2.42 - -$2.42
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$2.20-10.3%
    60d ago-$2.20-10.3%
    30d ago-$2.20-10.3%
    7d ago-$2.20-10.3%
    Current-$2.42
    Revenue Consensus
    $23.25M
    Range$17.50M - $29.00M
    2 analysts

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCF-0.31xFCF Yield-320.17%
    Profitability
    Profit Margin0.00%Operating Margin-436.20%
    ROE-84.10%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio4.57xQuick Ratio4.47x
    Trading Statistics
    Beta1.90Avg Volume1.08M
    52-Week High$20.5652-Week Low$2.90

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 61.7% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 11.0, below 30, the oversold line.

    Moving Averages

    SMA 10$4.12
    SMA 20$4.72
    SMA 50$7.51
    SMA 200$11.72
    EMA 10$3.92
    EMA 20$4.77
    EMA 50$6.90
    EMA 200$12.08

    MACD

    Line: -1.16Signal: -1.11Hist: -0.05

    ADX

    ADX: 67.5+DI: 5.0-DI: 46.7

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$4.69

    Bollinger Bands

    Upper Band$6.43
    Lower Band$3.01
    %B Position7253%(Upper)
    Band Width-0.04

    RSI (14-Day)

    Oversold
    11.0

    Momentum Oscillators

    Stoch %K2.7
    Stoch %D3.1
    Williams %R-97.4
    ROC (10d)-44.1%
    Momentum-2.27
    CCI (20d)-189.1
    MFI (14d)13.4

    Volatility Measures

    ATR (14d)$0.46(16.0%)
    StdDev (20d)0.86
    Hist Vol78.3%(High)

    Volume Flow

    VWAP$2.92
    OBV-60.8M
    AD Line-49.7M
    CMF (20d)-0.413

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio1.1x
    VWMA (20d)$4.34

    Pivot Points

    R3$3.56
    R2$3.40
    R1$3.21
    Pivot Point$3.05
    S1$2.86
    S2$2.70
    S3$2.51

    Advanced Oscillators

    TSI-70.79
    Ultimate Osc27.3
    KST-421.79

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about TNXP

    News

    TNXP Valuation

    GNG's valuation label for TNXP is Overvalued.

    P/FCF
    -0.3x
    P/B
    0.3x
    TNXP valuation multiples

    TNXP Profitability: Margins, ROIC and FCF

    Tonix Pharmaceuticals Holding (TNXP) has a gross margin of 89.3%, an operating margin of -436.2% and a net margin of 0.0%. It posts a -395.0% FCF margin.

    Gross margin
    89.3%
    Operating margin
    -436.2%
    Net margin
    0.0%
    ROE
    -84.1%
    FCF margin
    -395.0%
    FCF yield
    -320.2%
    TNXP financial statements

    Tonix Pharmaceuticals Holding Competitors

    The companies most similar to Tonix Pharmaceuticals Holding (TNXP) include Tenax Therapeutics, Grace Therapeutics and Mink Therapeutics.

    Sector: Healthcare

    Companies most similar to Tonix Pharmaceuticals Holding

    TNXP Analyst Ratings

    Tonix Pharmaceuticals Holding (TNXP) has a Buy consensus from 4 analysts: 4 Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell.

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    0
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0
    TNXP stock forecast

    TNXP Bull Case vs Bear Case

    Bull case

    • TNXP grew quarterly revenue 423.8% year over year.

    Bear case

    • TNXP beat EPS estimates in 25.0% of its last 8 reported quarters.

    TNXP Earnings: Beat Rate and Next Report

    Tonix Pharmaceuticals Holding (TNXP) beat the EPS estimate in 2 of the last 8 quarters (25.0%). Its next report is expected on Mar 10, 2027.

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -41.0%
    EPS estimate (fiscal period ending Dec 31, 2026)
    -$2.41
    TNXP earnings history

    TNXP Earnings Date

    TNXP reports Mar 10, 2027. The date is estimated.

    TNXP Earnings Call

    The latest TNXP earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    See insider activity

    Updated Nov 9, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Frequently Asked Questions About TNXP

    When does TNXP report earnings?

    Tonix Pharmaceuticals Holding Corp (TNXP) is expected to report earnings on Mar 10, 2027.

    Does TNXP pay dividends?

    Tonix Pharmaceuticals Holding Corp (TNXP) does not currently pay a regular dividend.

    What is TNXP's market cap?

    Tonix Pharmaceuticals Holding Corp (TNXP) has a market capitalization of $58.49M with a current stock price of $2.88.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.